No Data
No Data
Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate
Pyxis Oncology Will Present New Preclinical Data Supporting Development Of First-In-Concept Antibody-Drug Conjugate Targeting EDB+FN In Tumor Microenvironment At AACR 2025
Express News | Pyxis Oncology To Present Preclinical Data On Potential Of PYX-201 At AACR 2025, Apr. 28